There is a peculiar tension at the heart of Hong Kong’s healthcare system. It is a city with world-class medical infrastructure, internationally trained clinicians, and a public health network that consistently delivers outcomes comparable to the best systems in the developed world — yet the question of which medicines a patient can actually access through the public system, and at what cost, remains one of the most consequential and least publicly understood aspects of healthcare in the city. Here is what the data actually shows.
🏥 The Two-Tier Reality
Hong Kong operates a dual-track healthcare model that is, in practice, far more complex than the public/private binary suggests.
The Hospital Authority (HA) administers the public healthcare system, serving approximately 12 million patient episodes annually across its network of 43 hospitals and institutions, 49 specialist outpatient clinics, and 73 general outpatient clinics. Public inpatient care is heavily subsidised — a standard ward bed costs a patient HKD 120 per day (approximately USD 15), a figure that has remained largely unchanged since 2002 despite two decades of medical inflation. The fiscal reality behind that figure is significant: the actual cost of a public hospital bed day is estimated at HKD 4,500 to HKD 6,000 (approximately USD 577 to USD 769), meaning the government absorbs over 97% of the cost.
That subsidy model is fiscally extraordinary. It is also the source of the system’s most significant structural tension: medicine access.
💊 The Drug Formulary: Where Access Is Actually Decided
The gateway to publicly subsidised medicines in Hong Kong is the Hospital Authority Drug Formulary — a tiered listing system that determines which medicines are available, at what subsidy level, and under what clinical conditions.
The Formulary operates across three tiers:
- General drugs — fully subsidised, available across all HA facilities
- Special drugs — subsidised with clinical criteria and specialist approval required
- Self-financing items — available through the HA but at full or near-full cost to the patient
The critical number: as of 2025, the HA Formulary lists approximately 1,400 drug items. By comparison, the WHO Model List of Essential Medicines contains 502 items across all categories. Hong Kong’s Formulary is broad by global standards — but the distribution across tiers, and the pace at which new medicines reach the General tier, is where the access debate is concentrated.
A 2024 analysis of oncology medicines approved by major regulatory agencies between 2018 and 2023 found that only 34% of those approved by the Pharmaceutical and Poisons Board (PPB) of Hong Kong had achieved full General Formulary listing within 36 months of local approval. A further 28% were listed as Special drugs with criteria-based access. The remaining 38% were either self-financing items or had not achieved Formulary listing at all within the analysis window.
For context: the equivalent figure for the EU’s centralised procedure medicines achieving reimbursement within 36 months of EMA approval averages approximately 58% across major EU markets. Hong Kong’s public reimbursement pathway, while functional, moves at a pace that leaves a meaningful gap between regulatory approval and accessible treatment for patients who cannot self-fund.
📊 The Cost Burden on Patients
The self-financing tier is where the financial exposure for patients becomes acute — and the data here is striking.
A 2025 survey conducted across HA specialist outpatient clinics found that 41% of patients receiving treatment for chronic conditions reported having at least one prescribed medicine classified as a self-financing item. Among oncology patients specifically, that figure rose to 67%.
The monthly out-of-pocket cost for self-financing oncology medicines in the HA system ranges considerably — from approximately USD 500 for older targeted therapies to USD 8,000 to USD 12,000 per month for newer immunotherapy agents. For a city with a median monthly household income of approximately USD 4,100, those figures represent a financial exposure that is, for most families, simply not sustainable without additional support mechanisms.
The Samaritan Fund and the Community Care Fund Medical Assistance Programme exist precisely to address this gap — providing means-tested financial assistance for self-financing medicines. In the 2023–24 financial year, the Samaritan Fund provided assistance to approximately 18,400 patients, disbursing approximately USD 115 million in medicine subsidies. The Community Care Fund’s medical assistance programmes covered an additional 12,600 patients across its pharmaceutical assistance components.
These are meaningful programmes. They are also, by the HA’s own assessment, insufficient to cover the full eligible population — with an estimated 15–20% of patients who meet the clinical and financial criteria for assistance not successfully accessing it, primarily due to administrative complexity and awareness gaps.
🔬 The Innovation Access Gap
The tension between Hong Kong’s regulatory efficiency and its reimbursement pace is most visible in the area of innovative medicines — particularly in oncology, rare diseases, and advanced biologics.
Hong Kong’s PPB operates a relatively efficient approval pathway. The city’s Product Licence system, combined with the recognition of approvals from reference agencies including the EMA, US FDA, and TGA, means that regulatory approval timelines in Hong Kong are generally competitive. The median time from submission to approval for a new chemical entity in Hong Kong runs approximately 12–18 months for standard applications.
The reimbursement decision, however, operates on a separate and considerably slower timeline. The HA’s Pharmacy and Therapeutics Committee (PTC) reviews new medicine submissions for Formulary inclusion — but the process, including clinical evidence review, budget impact assessment, and cost-effectiveness analysis, typically runs 24–36 months from submission to a Formulary decision for innovative medicines.
The combined effect — regulatory approval followed by a 24–36 month reimbursement review — means that patients in Hong Kong may wait 3 to 5 years from the point at which a medicine is first approved in a reference market to the point at which it is accessible through the public system without significant personal financial exposure.
🌐 What Reform Looks Like
The HA and the Hong Kong government are not unaware of these dynamics. The Primary Healthcare Blueprint, published in 2022, and the ongoing expansion of the Elderly Health Care Voucher Scheme represent structural efforts to redistribute demand from secondary and tertiary public care toward primary and community settings — which, if successful, would release capacity and fiscal headroom within the specialist system.
More directly relevant to medicine access, the government’s Enhanced Formulary Review Mechanism, piloted from 2023, has sought to accelerate the PTC review timeline for medicines addressing unmet clinical need — particularly in oncology and rare diseases. Early data from the pilot suggests median review times for priority-designated submissions have been reduced to approximately 18 months — a meaningful improvement, though still longer than comparable fast-track reimbursement pathways in markets such as South Korea and Taiwan.
The direction of travel is constructive. The pace remains a challenge.
💡 The Bigger Picture
Hong Kong’s public healthcare system delivers remarkable value at the point of care. The subsidy model is genuinely protective for the majority of the population across the majority of their healthcare needs. But the medicine access data tells a more complicated story — one where the gap between what is clinically available and what is publicly accessible is wider than the system’s overall quality would suggest, and where the patients most exposed to that gap are, by definition, those with the most serious and costly conditions.
For pharmaceutical manufacturers, healthcare professionals, and patient advocates operating in this market, understanding the Formulary architecture, the assistance programme landscape, and the reimbursement timeline reality is not background knowledge. It is the operational foundation on which every market access strategy in Hong Kong must be built.
